

# VAN MEDICAL JOURNAL

## ARTICLE STRUCTURE SAMPLE

**IMPORTANT: This main manuscript file must be ANONYMOUS. Do not include author names, affiliations, or any identifying information.**

---

**TITLE** (Concise and informative; max 150 characters; fully reflect the content)

*Example: "Prognostic Value of Serum Lactate Levels in Patients Admitted to the Intensive Care Unit: A Prospective Cohort Study"*

**ABSTRACT** (200–300 words for Original Articles; 150–250 words for Case Reports)

SECTION	CONTENT GUIDANCE
Introduction	Briefly state the purpose and rationale of the study.
Materials & Methods	Describe study design, setting, and participants. For Clinical Trials: include the Trial Registration Number (TRN) and registration date.
Results	Present the main findings with specific data and statistical significance.
Conclusion	Summarize the main implications of the findings.

**Keywords:** Keyword 1; Keyword 2; Keyword 3 (Select 3–6 terms from Medical Subject Headings — MeSH; separate with semicolons; use lowercase except proper nouns; do not use abbreviations)

### INTRODUCTION

- State the background, rationale, and specific objectives of the study.
- Identify the gap in current knowledge that the study addresses.
- Cite relevant and current literature (at least 50% of references from the last 5 years).
- End with a clear statement of the study aim or hypothesis.

### MATERIALS AND METHODS

**Study Design and Participants:** Describe the study design (e.g., randomized controlled trial, retrospective cohort study). Explain participant selection criteria.

**SAGER Guideline Note:** Report the sex and/or gender of study participants and the method used to determine them.

**Reporting Guideline:** Follow the appropriate checklist: CONSORT (RCTs), STROBE (observational), PRISMA (systematic reviews), CARE (case reports), STARD (diagnostic studies).

**Ethical Approval:** Explicitly state that the study was conducted in accordance with the Declaration of Helsinki.

*Example: "Ethics Committee approval was obtained from the Clinical Research Ethics Committee of [BLINDED] University (Date: 12.04.2022, Decision No: 21)."*

Do not write the institution name explicitly — use "[BLINDED]" to ensure double-blind review.

**Clinical Trial Registration:** State the registry name, TRN, and registration date. Registration must be prospective (at or before first patient enrollment).

*Example: "This trial was registered at ClinicalTrials.gov (TRN: NCT00000000, Date: 01.01.2022)."*

**Statistical Analysis:** Specify the software used (name, version, company, city, country) and all statistical tests applied.

## RESULTS

- Present results in a logical sequence, using subheadings where necessary.
- Do not repeat data already presented in tables or figures.
- Report effect sizes and confidence intervals, not just p-values.

## DISCUSSION

- Interpret results in the context of existing literature.
- Do not simply repeat the results.
- Discuss the clinical or scientific implications of your findings.

**Study Limitations:** Explicitly state the limitations of the study (e.g., small sample size, retrospective design, single-center nature).

## CONCLUSION

- Link conclusions directly to the study objectives.
- Avoid unqualified statements not supported by the data.
- State practical implications or recommendations where appropriate.

**DECLARATIONS** (Required section — must appear before References)

**Ethics Statement:** "Ethics Committee approval was obtained from [BLINDED] University Clinical Research Ethics Committee (Date: ..., Decision No: ...). The study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants."

**Author Contributions** (CRediT Taxonomy — use initials to maintain anonymity during review):

*Example: Conceptualization: A.D., S.L.; Methodology: S.L., A.B.; Formal Analysis: B.C.; Data Collection: A.B., B.C.; Writing – Original Draft: A.D.; Writing – Review & Editing: C.D., A.D.; Supervision: M.N.*

**Data Availability Statement** (choose one):

- "The data that support the findings of this study are available from the corresponding author upon reasonable request."
- "The datasets generated during the current study are available in the [NAME] repository, [LINK]."
- "Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study."

**Use of AI Tools** (choose one):

- "No Artificial Intelligence (AI) tools were used in the preparation of this manuscript."
- "AI tools ([Name of Tool], [Version]) were used for [purpose: e.g., language editing]. All content was reviewed and verified by the authors, who take full responsibility."

**Conflict of Interest:** "The authors declare no conflict of interest." OR specify the nature of the conflict.

**Funding:** "No financial support was received for this study." OR "This study was supported by [Institution/Agency] (Grant No: ...)."

**REFERENCES**

Use Vancouver/NLM style. Number consecutively in order of appearance. At least 50% of references must be from the last 5 years. Include DOI for all references where available.

**Journal:** Greenblatt DJ, Harmatz JS, Zinny MA, Shader RI. Effect of gradual withdrawal on the rebound sleep disorder after discontinuation of triazolam. *N Engl J Med*.

1987;317(12):722–728. doi:10.1056/NEJM198709173171206

**Book:** Ringsven MK, Bond D. Gerontology and leadership skills for nurses. 2nd ed. Albany (NY): Delmar Publishers; 1996.

**Website:** Health Statistics Yearbook 2018. Ministry of Health. Available at: [URL].

Accessed: 27 October 2024.

List all authors if 6 or fewer. If 7 or more, list the first 6 followed by "et al."

**TABLES** (Embed in document, one per page; max 5 tables)

*Table 1. Clinical features of patients with OSA (title above table)*

Variable	Group A (n=30)	Group B (n=30)	p-value
Age (years)	45.2 ± 5.1	48.1 ± 4.9	0.042
BMI (kg/m <sup>2</sup> )	28.1 ± 3.2	27.5 ± 2.8	0.315

*Note: Explanatory footnotes and abbreviation keys go below the table.*

**FIGURE LEGENDS** (List all legends here; upload figure files separately in the submission system as JPEG/TIFF, min 300 dpi)

Figure 1. Comparison of serum glucose levels between groups at baseline and 6-month follow-up. Error bars represent standard deviation.

Figure 2. Histopathological examination of tissue samples. Hematoxylin and eosin staining (×200).